ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      4,967.23
      -0.88%
      US Tech 100
      16,570.00
      -2.16%
      Dow Jones
      37,986.40
      0.56%
      Brent Oil
      86.625
      0.24%
      Bitcoin
      64,261.78
      1.20%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Chemomab Therapeutics Ltd (CMMB)

      7. Chemomab Therapeutics Ltd (CMMB) News

      CMMB

      Chemomab Therapeutics (CMMB)

      Chemomab Therapeutics Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CMMB
      DateTimeSourceHeadlineSymbolCompany
      04/18/20247:00AMGlobeNewswire Inc.Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
      04/02/20247:00AMGlobeNewswire Inc.Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024NASDAQ:CMMBChemomab Therapeutics Ltd
      03/25/20247:06AMGlobeNewswire Inc.Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
      03/07/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
      03/07/20247:00AMPR Newswire (US)Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
      03/05/20247:00AMPR Newswire (US)Chemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
      02/20/20249:20AMAllPennyStocks.comBiotech Shares Massively Bid Up Before Opening BellNASDAQ:CMMBChemomab Therapeutics Ltd
      02/20/20247:00AMPR Newswire (US)Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesNASDAQ:CMMBChemomab Therapeutics Ltd
      02/14/20247:00AMPR Newswire (US)Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
      02/05/20247:00AMPR Newswire (US)Chemomab Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
      01/30/20247:00AMPR Newswire (US)Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
      01/03/20247:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
      01/03/20247:00AMPR Newswire (US)Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024NASDAQ:CMMBChemomab Therapeutics Ltd
      11/16/20237:00AMPR Newswire (US)Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
      11/15/20234:35PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
      11/15/20237:00AMPR Newswire (US)Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
      11/13/20238:00AMPR Newswire (US)Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023NASDAQ:CMMBChemomab Therapeutics Ltd
      11/09/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
      11/09/20238:00AMPR Newswire (US)Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
      11/06/20234:15PMPR Newswire (US)Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price RequirementNASDAQ:CMMBChemomab Therapeutics Ltd
      11/06/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMMBChemomab Therapeutics Ltd
      10/30/20238:33AMEdgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
      10/30/20237:00AMPR Newswire (US)Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
      10/26/20237:00AMPR Newswire (US)Chemomab Therapeutics to Present at Upcoming Scientific ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
      10/16/20234:25PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CMMBChemomab Therapeutics Ltd
      09/28/20237:00AMPR Newswire (US)Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
      08/29/20237:00AMPR Newswire (US)Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
      08/14/20238:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
      08/14/20238:00AMPR Newswire (US)Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
      08/08/20236:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
       Showing the most relevant articles for your search:NASDAQ:CMMB